Proactive Investors
27 May 2026, 06:46 UTC · 2h ago
ImmuPharma focused on securing P140 licensing deal in 2026
Source · https://www.proactiveinvestors.co.uk/companies/news/1092936
Read source
Search tags
Proactive Investors
27 May 2026, 06:46 UTC · 2h ago
Source · https://www.proactiveinvestors.co.uk/companies/news/1092936
Read sourceSearch tags
Story key points
5 claims · impact-rated
ImmuPharma is in active discussions with global commercial partners and targets a licensing transaction for its P140 therapy this year. — A licensing deal for a core asset is a primary value catalyst for small-cap biotech firms and significantly alters valuation.
+0.80ImmuPharma has begun activities to support an IND application for Kapiglucagon, including a pre-IND meeting with the US FDA. — Advancing toward FDA clinical trials represents a critical milestone in the drug development pipeline and reduces binary risk.
+0.60ImmuPharma completed a £6.47 million fundraise in April, increasing year-end cash to £1.4 million. — Stronger liquidity reduces the immediate risk of bankruptcy or emergency dilutive funding for a loss-making company.
+0.40Empire Metals delivered high-grade titanium intercepts above 7% TiO2 at the Pitfield project in Western Australia. — Strong drilling results increase the probability of a commercially viable deposit, though the snippet lacks full project scale.
+0.30ImmuPharma reported a narrowed loss of £1.8 million for the period ending December 31, down from £2.5 million in 2024. — Improving the bottom line is positive, though secondary to clinical and partnering milestones in biotech.
+0.20Impact vectors
1 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Ticker attribution
Model heads
The company delivered strong early results and high-grade intercepts from its largest ever drilling campaign.
The company is in active partnership discussions for its lead therapy, narrowed its losses, and successfully completed a fundraise.
No ticker relationship head found.